John R. Neefe

2.2k total citations
51 papers, 888 citations indexed

About

John R. Neefe is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John R. Neefe has authored 51 papers receiving a total of 888 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in John R. Neefe's work include Immunotherapy and Immune Responses (9 papers), T-cell and B-cell Immunology (6 papers) and Hepatitis B Virus Studies (5 papers). John R. Neefe is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), T-cell and B-cell Immunology (6 papers) and Hepatitis B Virus Studies (5 papers). John R. Neefe collaborates with scholars based in United States, United Kingdom and Netherlands. John R. Neefe's co-authors include Stephen E. Goldstone, Joel M. Palefsky, Geoffrey R. Weiss, Laura F. Hutchins, Philip S. Schein, Robert B. Livingston, Charles W. Taylor, Frederick P. Smith, John Crowley and Steven M. Grunberg and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

John R. Neefe

49 papers receiving 759 citations

Peers

Countries citing papers authored by John R. Neefe

Since Specialization

Citations

This map shows the geographic impact of John R. Neefe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Neefe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Neefe more than expected).

Fields of papers citing papers by John R. Neefe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Neefe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Neefe. The network helps show where John R. Neefe may publish in the future.

Co-authorship network of co-authors of John R. Neefe

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Neefe. A scholar is included among the top collaborators of John R. Neefe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Neefe. John R. Neefe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis: Final Results of an Open-Label Trial 2005 ·Annals of Otology Rhinology & Laryngology ·Craig S. Derkay, Richard J. Smith, John E. McClay, Jo‐Anne H. van Burik, Brian J. Wiatrak, James E. Arnold, (unknown), John R. Neefe	63
2	Activity of HspE7, a Novel Immunotherapy, in Patients with Anogenital Warts 2002 ·Diseases of the Colon & Rectum ·Stephen E. Goldstone, Joel M. Palefsky, (unknown), John R. Neefe	69
3	Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study 1994 ·Cancer ·Julie A. Kish, Michael Wolf, E. David Crawford, Joseph T. Leimert, Anton J. Bueschen, John R. Neefe, (unknown)	39
4	Phase II Evaluation of Amonafide in Advanced Sarcoma: A Southwest Oncology Group Study 1994 ·Cancer Investigation ·Saundra S. Buys, Barbara Metch, Stanley P. Balcerzak, John R. Neefe, W. J. Stuckey	2
5	Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study 1993 ·Cancer ·Robert B. Livingston, (unknown), John J. Crowley, Stephen K. Williamson, Frederick J. Meyers, Timothy J. O’Rourke, John R. Neefe	3
6	Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. 1993 ·Journal of Clinical Oncology ·David R. Gandara, John Crowley, Robert B. Livingston, Edith A. Perez, Charles W. Taylor, Geoffrey R. Weiss, John R. Neefe, Laura F. Hutchins, Ralph W. Roach, Steven M. Grunberg	121
7	5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules 1993 ·Cancer ·William J. John, John R. Neefe, John S. Macdonald, (unknown), (unknown)	9
8	Phase II Trial of Recombinant DNA ?? -Interferon in Advanced Colorectal Cancer: A Southwest Oncology Group Study 1991 ·Journal of Immunotherapy ·Thomas D. Brown, Phyllis J. Goodman, (unknown), John S. Macdonald, (unknown), Sarah A. Taylor, John R. Neefe, Ellen R. Gaynor	4
9	Abrogation of interferon-induced resistance to interferon-activated major histocompatibility complex-unrestricted killers by treatment of a melanoma cell line with 5-fluorouracil. 1991 ·PubMed ·John R. Neefe, Jacob L. Glass	16
10	Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. 1991 ·PubMed ·John R. Neefe, William J. John	16
11	A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. 1990 ·PubMed ·Robert P. Whitehead, Thomas R. Fleming, John S. Macdonald, Phyllis J. Goodman, John R. Neefe, Thomas J. Braun, Lode J. Swinnen, Evan M. Hersh	21
12	LACK OF COMMON HAPLOTYPE AMONG FOUR FAMILY MEMBERS WITH LATE‐ONSET KAPOSI'S SARCOMA 1989 ·International Journal of Immunogenetics ·John R. Neefe, Joseph Treat, (unknown), Philip S. Schein, A. Holly Johnson	2
13	Therapy of Advanced Gastric Carcinoma 1989 ·American Journal of Clinical Oncology ·Joseph Treat, (unknown), Paul V. Woolley, James D. Ahlgren, John R. Neefe, Frederick P. Smith, John S. Macdonald, Philip S. Schein	3
14	A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer 1984 ·Cancer ·(unknown), James D. Ahlgren, John R. Neefe, John Rothman, Seth A. Rudnick, (unknown), Philip S. Schein	30
15	Phase II trial of mitoxantrone in advanced colorectal cancer. 1982 ·PubMed ·(unknown), (unknown), (unknown), (unknown), John R. Neefe, (unknown), Schein Ps	4
16	Specific elimination of cytotoxic effector cells. I. Adsorptive behavior of effectors and their precursors and spleen cell monolayers. 1976 ·The Journal of Experimental Medicine ·John R. Neefe, David H. Sachs	16
17	Pathology of modified graft-versus-host disease in bone marrow allografted monkeys treated with antilymphocyte serum 1975 ·Annals of Hematology ·G. R. F. Krueger, Robert G. Graw, G. Nicholas Rogentine, (unknown), John R. Neefe, (unknown)	3
18	Rhesus Lymphocyte Alloantigens.III.Identification of New Antigens 1975 ·Tissue Antigens ·John R. Neefe, Ethan Ellis, G. Nicholas Rogentine	7
19	PREVALENCE AND NATURE OF HEPATIC DISTURBANCE FOLLOWING ACUTE VIRAL HEPATITIS WITH JAUNDICE 1955 ·Annals of Internal Medicine ·John R. Neefe, (unknown), (unknown), (unknown), Gilbert W. Beebe, S. Jablon, J G Reinhold, (unknown)	32
20	The Clinical Usefulness of Acth and Cortisone in Liver Disease 1955 ·Gastroenterology ·(unknown), Lewis W. Bluemle, John R. Neefe, Paul György	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact